Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855206 | 1.00 | GAA (0.46) | GAATDP1CES2ALDH1A1MEN1 | |
| SCHEMBL853230 | 0.98 | GAA (0.42) | GAATDP1CES2ALDH1A1MEN1 | |
| SCHEMBL5234963 | 0.83 | GAA (0.40) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL854998 | 0.81 | GAA (0.39) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL853966 | 0.81 | GAA (0.36) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL4859801 | 0.79 | TDP1 (0.37) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL7400810 | 0.73 | ALDH1A1 (0.36) | GAACES2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL31327082 | 0.73 | GAA (0.38) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL16050086 | 0.69 | GAA (0.49) | GAATDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL24517944 | 0.65 | CES2 (0.35) | CES2ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234020-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. | 2005-10-20 | — | — | US | claimed |
| EP-1556059-A1 | THROMBOPOIETIN MIMETICS | Smithkline Beecham (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2003103686-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | claimed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | claimed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | claimed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | claimed |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-1793821-B1 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-3321255-A1 | NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE ATTRIBUTABLE TO ALS | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003103686-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234020-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | GAA 2853/4885TDP1 2922/4885CES2 4794/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | GAA 3532/4885TDP1 342/4885CES2 2886/4885 |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITF, EYA3, AQP1 | GAA 2572/4885TDP1 2439/4885CES2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.